Loss of 5-hydroxymethylcytosine in cancer: cause or consequence?

Area of Science:

• Epigenetics and Cancer Biology
• DNA Modifications
• Enzyme Function

Background:

• The discovery of TET1's enzymatic activity, converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), has highlighted 5hmC as a critical DNA modification in cancer.
• Tumors frequently exhibit reduced 5hmC levels compared to normal tissues, prompting investigation into its significance in tumorigenesis.
• The dual role of TET proteins (tumor-suppressive and oncogenic) adds complexity to understanding 5hmC's involvement in cancer.

Purpose of the Study:

• To review and synthesize recent findings on the role of 5-hydroxymethylcytosine (5hmC) in various cancers.
• To elucidate whether the depletion of 5hmC in tumors is a cause or a consequence of cancer development.
• To summarize the complex roles of TET proteins in cancer progression.

Main Methods:

• Literature review of experimental data and findings on TET proteins and 5hmC in cancer.
• Analysis of studies investigating TET1 and TET2 mutations and their impact on 5hmC levels.
• Examination of experimental evidence regarding the oncogenic and tumor-suppressive functions of TET proteins.

Main Results:

• Tet2 mutations are identified as drivers in hematological malignancies.
• Tet1 exhibits an oncogenic role in MLL-rearranged leukemia due to its overexpression.
• Overexpression of Tet2 in melanoma suppresses cancer progression by restoring the 5hmC landscape, while Tet1 inhibition in non-transformed cells does not induce transformation.

Conclusions:

• The role of 5hmC in cancer is multifaceted, with TET proteins displaying both tumor-suppressive and oncogenic activities depending on the context.
• Further research is needed to fully understand the causal relationship between 5hmC depletion and tumor development.
• The precise mechanisms by which TET proteins influence cancer progression warrant continued investigation.